GlassScriptPhysician profile
Summer D Cumba
NPI 1104927136
$1,122.68
in general payments reported to CMS, 2019-2025
26 companies · $49.19 in 2025
The $49.19 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $401 · 2023: $47.41 · 2024: $148 · 2025: $49.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.29 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $116.97 | 2022 | |
| Pfizer INC. | $96.21 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.56 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.39 | 2021 | |
| Novo Nordisk INC | $69.87 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $57.85 | 2021-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $41.31 | 2021-2022 | |
| Eisai INC. | $32.60 | 2021 | |
| Merck Sharp & Dohme LLC | $30.45 | 2021 | |
| Acerus Pharmaceuticals Corporation | $27.12 | 2022 | |
| Nestle Healthcare Nutrition INC. | $26.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.75 | 2024 | Jardiance |
| Exact Sciences Corporation | $23.31 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $18.47 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18.27 | 2022 | |
| Baxter Healthcare | $17.84 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Biohaven Pharmaceuticals, INC. | $15.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.66 | 2022 | |
| Adlon Therapeutics L.P. | $14.46 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.16 | 2025 | Airsupra |
| Philips North America LLC | $14.04 | 2022 | |
| Shield Therapeutics INC | $13.97 | 2022 | |
| Amarin Pharma, INC. | $13.35 | 2021 | |
| Almatica Pharma LLC | $13.08 | 2021 | |
| Phathom Pharmaceuticals, INC. | $3.37 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Cumba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.